We are live on !
Find out more
BC
Bruce & Co Portfolio holdings
AUM
$369M
Turnover
0%
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+50.95%
3 Year Est. Return
+94.54%
5 Year Est. Return
+93.1%
10 Year Est. Return
+271.31%
AUM
$369M
AUM Growth
+$19.8M
(+5.7%)
Cap. Flow
-$5.47M
Cap. Flow % of AUM
Cap. Flow %
-1.48%
Top 10 Holdings %
Top 10 Hldgs %
60.59%
Holding
41
New
–
Increased
4
Reduced
18
Closed
–
Avg Time Held
7
years
Top 10 Avg Time Held
5.3
years
Top 20 Avg Time Held
6.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$2.4M |
| 2 |
Beta Bionics
BBNX
|
+$1.37M |
| 3 |
Fate Therapeutics
FATE
|
+$370K |
| 4 |
AerCap
AER
|
+$213K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vicor
VICR
|
+$4.64M |
| 2 |
U-Haul Holding Co Series N
UHAL.B
|
+$1.74M |
| 3 |
Allstate
ALL
|
+$652K |
| 4 |
Apple
AAPL
|
+$572K |
| 5 |
NextEra Energy
NEE
|
+$543K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.37% |
| 2 | Utilities | 21.42% |
| 3 | Industrials | 18.52% |
| 4 | Financials | 8.53% |
| 5 | Technology | 7.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
LyondellBasell Industries
LYB
$20.6B
| $3.16M | 0.85% |
60,000
| – | – |
2025 Q2
4 quarters
|
|
27
Personalis
PSNL
$1.7B
| $3.12M | 0.85% |
233,000
| – | – |
2022 Q4
14 quarters
|
|
|
28
Fate Therapeutics
FATE
$223M
| $2.67M | 0.72% |
989,188
+200,000
| +25% | +$370K |
2019 Q4
26 quarters
|
|
29
Eli Lilly
LLY
$1.11T
| $2.4M | 0.65% |
2,000
| – | – |
2024 Q4
6 quarters
|
|
30
RLI Corp
RLI
$5.62B
| $2.36M | 0.64% |
40,000
-800
| -2% | -$42.9K |
2013 Q2
52 quarters
|
|
31
Apogee Enterprises
APOG
$871M
| $2.29M | 0.62% |
50,000
| – | – |
2026 Q1
1 quarter
|
|
32
EDAP TMS S.A.
FOCL
$192M
| $2.27M | 0.62% |
438,652
| – | – |
2013 Q2
52 quarters
|
|
33
SiriusXM
SIRI
$9.05B
| $1.65M | 0.45% |
55,784
| – | – |
2014 Q4
46 quarters
|
|
34
Venture Global Inc
VG
$32B
| $1.11M | 0.3% |
100,000
| – | – |
2025 Q1
5 quarters
|
|
35
Ashland
ASH
$3.26B
| $988K | 0.27% |
15,000
| – | – |
2013 Q2
52 quarters
|
|
36
Viatris
VTRS
$21B
| $916K | 0.25% |
57,696
-583
| -1% | -$9.04K |
2021 Q3
19 quarters
|
|
37
MannKind Corp
MNKD
$994M
| $831K | 0.22% |
195,073
| – | – |
2019 Q3
27 quarters
|
|
38
Bausch Health
BHC
$2.36B
| $611K | 0.17% |
124,000
| – | – |
2017 Q2
36 quarters
|
|
39
908 Devices
MASS
$472M
| $594K | 0.16% |
68,286
| – | – |
2022 Q4
14 quarters
|
|
40
WEC Energy
WEC
$34.9B
| $461K | 0.12% |
3,945
| – | – |
2024 Q2
8 quarters
|
|
41
Caribou Biosciences
CRBU
$49.7M
| $440K | 0.12% |
250,000
| – | – |
2023 Q1
13 quarters
|
|
Similar funds
EW
CCG
OG
ACA
WAOI
MLCM
CC
AWA
Bruce & Co's Q2 2026 Portfolio in Review
As of Q2 2026, Bruce & Co held 41 positions worth $369M, up 5.7% from $350M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Trading was light in Q2 2026: portfolio turnover was 0%. Bruce & Co opened no new positions and made no exits, leaving the 41-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 27% a quarter earlier, followed by Utilities and Industrials.
- Bruce & Co added most to Supernus Pharmaceuticals in Q2 2026, an estimated $2.4M increase.
- Bruce & Co's biggest Q2 2026 reduction was Vicor, cutting an estimated $4.64M.
- Bruce & Co's ten largest holdings make up 61% of its $369M portfolio in Q2 2026.
- Bruce & Co opened 0 new positions and closed 0 in Q2 2026.
- Bruce & Co's portfolio value rose 5.7% quarter-over-quarter to $369M.
Based on Bruce & Co's 13F filing for Q2 2026, filed 14 Aug 2026.